Beijing Tong Ren Tang Chinese Medicine Company Limited
Beijing Tong Ren Tang Chinese Medicine Company Limited Fundamental Analysis
Beijing Tong Ren Tang Chinese Medicine Company Limited (3613.HK) shows strong financial fundamentals with a PE ratio of 12.06, profit margin of 27.05%, and ROE of 13.17%. The company generates $2.0B in annual revenue with moderate year-over-year growth of 5.69%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 64.4/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze 3613.HK's fundamental strength across five key dimensions:
Efficiency Score
Excellent3613.HK demonstrates superior asset utilization.
Valuation Score
Excellent3613.HK trades at attractive valuation levels.
Growth Score
Moderate3613.HK shows steady but slowing expansion.
Financial Health Score
Excellent3613.HK maintains a strong and stable balance sheet.
Profitability Score
Moderate3613.HK maintains healthy but balanced margins.
Key Financial Metrics
Is 3613.HK Expensive or Cheap?
P/E Ratio
3613.HK trades at 12.06 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, 3613.HK's PEG of 0.12 indicates potential undervaluation.
Price to Book
The market values Beijing Tong Ren Tang Chinese Medicine Company Limited at 1.55 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 12.33 times EBITDA. This signals the market has high growth expectations.
How Well Does 3613.HK Make Money?
Net Profit Margin
For every $100 in sales, Beijing Tong Ren Tang Chinese Medicine Company Limited keeps $27.05 as profit after all expenses.
Operating Margin
Core operations generate 31.89 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $13.17 in profit for every $100 of shareholder equity.
ROA
Beijing Tong Ren Tang Chinese Medicine Company Limited generates $11.53 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Beijing Tong Ren Tang Chinese Medicine Company Limited generates strong operating cash flow of $523.68M, reflecting robust business health.
Free Cash Flow
Beijing Tong Ren Tang Chinese Medicine Company Limited generates strong free cash flow of $491.31M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $0.59 in free cash annually.
FCF Yield
3613.HK converts 7.58% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
12.06
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.12
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.55
vs 25 benchmark
P/S Ratio
Price to sales ratio
3.26
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.03
vs 25 benchmark
Current Ratio
Current assets to current liabilities
19.65
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.13
vs 25 benchmark
ROA
Return on assets percentage
0.12
vs 25 benchmark
ROCE
Return on capital employed
0.14
vs 25 benchmark
How 3613.HK Stacks Against Its Sector Peers
| Metric | 3613.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 12.06 | 28.54 | Better (Cheaper) |
| ROE | 13.17% | 738.00% | Weak |
| Net Margin | 27.05% | -43982.00% (disorted) | Strong |
| Debt/Equity | 0.03 | 0.34 | Strong (Low Leverage) |
| Current Ratio | 19.65 | 2806.01 | Strong Liquidity |
| ROA | 11.53% | -14624.00% (disorted) | Strong |
3613.HK outperforms its industry in 5 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Beijing Tong Ren Tang Chinese Medicine Company Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
12.50%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
-10.04%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
-139.43%
Industry Style: Defensive, Growth, Innovation
Declining